Physician profile
Jesus Perez
NPI 1639142961
$280,784.86
in general payments reported to CMS, 2019-2025
33 companies · $35K in 2025
The $35K reported for 2025 was more than what 95% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91K · 2020: $30K · 2021: $31K · 2022: $24K · 2023: $31K · 2024: $38K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $83K · Travel and Lodging: $14K · Food and Beverage: $4,025 · Honoraria: $2,800 · Consulting Fee: $725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $82,699.99 |
| Travel and Lodging | $14,155.10 |
| Food and Beverage | $4,024.78 |
| Honoraria | $2,800.00 |
| Consulting Fee | $725.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $160,870.33 | 2019-2025 | Evenity, Prolia, Prolia |
| Novo Nordisk INC | $92,613.37 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $9,291.15 | 2019 | |
| Ascendis Pharma Endocrinology INC | $6,221.51 | 2023-2025 | Yorvipath |
| Corcept Therapeutics | $4,010.45 | 2019 | |
| Horizon Therapeutics Plc | $2,937.79 | 2021-2023 | Tepezza |
| Lilly USA, LLC | $2,214.43 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $725.00 | 2023 | Strensiq |
| Clarus Therapeutics INC. | $500.00 | 2020 | |
| Radius Health, INC. | $186.74 | 2019-2022 | |
| Mannkind Corporation | $125.00 | 2019 | |
| Xeris Pharmaceuticals, INC. | $114.86 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $110.15 | 2022 | |
| Tandem Diabetes Care, INC. | $103.93 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $99.44 | 2025 | Twiist |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $70.88 | 2019 | |
| Beta Bionics, INC. | $65.94 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Recordati_rare_diseases_inc. | $59.89 | 2021 | |
| Dexcom, INC. | $56.54 | 2019-2020 | |
| Abbott Laboratories | $55.15 | 2019-2025 | Freestyle Libre 3 |
| Ipsen Biopharmaceuticals, INC | $50.00 | 2019 | |
| Neurocrine Biosciences, INC. | $44.16 | 2025 | |
| Insulet Corporation | $40.47 | 2019-2022 | |
| Baylis Medical Technologies INC. | $34.43 | 2024 | |
| Rhythm Pharmaceuticals, INC. | $32.74 | 2021 | |
| Medtronic, INC. | $30.52 | 2023 | Minimed 780g, Minimed 770g |
| Antares Pharma, INC. | $20.13 | 2019 | |
| Valeritas, INC. | $18.88 | 2019 | |
| Kyowa Kirin, INC. | $16.95 | 2023 | Crysvita |
| Boston Scientific Corporation | $16.76 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.53 | 2023 | |
| Lifescan, INC. | $16.19 | 2019 | |
| Siemens Medical Solutions USA, INC. | $14.55 | 2023 | Naeotom Alpha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesus Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.